RDIF and SK-Pharmacy agree to supply Sputnik V vaccine to Kazakhstan

Press release, 26.08.2020

Moscow, August 26, 2020 – The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and SK-Pharmacy, a Kazakh company, have announced an agreement for the supply of the Russian Sputnik V vaccine to Kazakhstan.

SK-Pharmacy is a sole distributor for the Ministry of Health of the Republic of Kazakhstan. It is expected that the batch of the vaccine to be delivered to the country will be produced by one of RDIF’s international partners.

On August 11, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world’s first registered vaccine against COVID-19. Detailed information on the Sputnik V vaccine, the technological platform of human adenoviral vectors used to create the vaccine, and other details are available at sputnikvaccine.com


Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling more than RUB1.9 tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn. Further information can be found at rdif.ru

For additional information contact:
Arseniy Palagin
Russian Direct Investment Fund
Press Secretary
Tel: +7 495 644 34 14, ext. 2395
Mobile: +7 916 110 31 41
E-mail: arseniy.palagin@rdif.ru

Andrew Leach / Maria Shiryaevskaya
Hudson Sandler
Tel: +44 (0) 20 7796 4133